Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Firibastat MR vs IR in Healthy Males
NCT03714685Phase 1Completed
- Sponsor
- Quantum Genomics
- Start
- Feb 2019
- Primary completion
- May 2019
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of firibastat in hypertension (HTN), sponsored by Quantum Genomics. Primary endpoints: Maximum Plasma Concentration, Time to Cmax and 1 more. Started Feb 2019; status: completed.
02
Drugs
firibastat
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03714685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03714685.